Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 129 Carcinoma, Renal Cell 36 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Neoplasms 27 Cholangiocarcinoma 23 Endometrial Neoplasms 19 Liver Neoplasms 16 Melanoma 15 Thyroid Neoplasms 13 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Biliary Tract Neoplasms 12 Neoplasm Metastasis 9 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Ovarian Neoplasms 8 Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Triple Negative Breast Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Small Cell Lung Carcinoma 5 Neuroendocrine Tumors 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Adenocarcinoma 4 Thyroid Cancer, Papillary 3 Solid Tumors 3

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × GIST × lenvatinib × Clear all

NCT07096609 2026-04-03

LONGIST

Asan Medical Center

Phase 1/2 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡